• Skip to main content

Alcohol Review

Alcohol understanding for all

  • Highlights
  • Alcohol Review 2025
  • Get more
  • Connect
  • Log In

Alcohol Review – Issue 110, January 31st 2025

January 31, 2025 by philcain

Read on the homepage
Become a full subscriber

In this issue:
Invitation: Join Alcohol Review 2025
News: Outgoing Biden US Surgeon General sparks cancer warning debate; Investor drops alcohol stake; Psychedelic efforts hit high; Lo-no policy warning ignored; App assessed.
Features: Opinion: Alcohol-free beer hype is unhelpful; The case for pure free time hedonism; Put alcohol pleasure in perspective

Invitation

Alcohol Review 2025: Winning the narrative, sharing the benefits. With live sessions from acclaimed author Grant Ennis and UK public health leader Alice Wiseman. Impactful Spotlight sessions will highlight a series of cutting-edge developments. Full subscribers go free.
Subscribe, register and propose a session.

News

Outgoing Biden US Surgeon General sparks global cancer warning debate: Alcohol’s cancer risk made global headlines when outgoing Biden-appointed US Surgeon General said that alcohol products should carry warning labels. It is unclear which direction the nascent Trump administration will go with alcohol policy. In the meantime Pennsylvania House Representative Jose Giral proposed a bill which would require alcohol products in the Commonwealth to carry a warning. And Alaska revisited a plan to use signs to warn about cancer at point of sale. A second report was released to inform this year’s highly contested guideline revision. In India, meanwhile, the Bombay High Court last week notified central and state governments of a public interest litigation from a 24-year-old campaigner who wants to see alcohol cancer warning labels.

Investor drops alcohol stake: Investment manager Terry Smith dropped a long-held stake in alcohol giant Diageo, citing concerns over its new management team and the possibility that weight-loss drugs will reduce alcohol demand.

Psychedelic efforts hit high: Shares in the UK’s Solvonis Therapeutics Plc jumped after the FDA said it would allow its ketamine-based drug for alcohol problems to progress to phase two clinical trials. Separately, dimethyltryptamine (DMT), the active element in the traditional South American drug ayahuasca, is also to be investigated.


Lo-no policy warning ignored: Low-alcohol products carrying alcohol brands should face the same marketing restrictions as full-strength counterparts and always be cheaper, says new guidance from the UK’s Alcohol Health Alliance. Their producers should also not be part of policy discussion. This suggestion has yet to be heeded, however, with Public Health Minister Andrew Gwynne MP this week joining an alcohol industry lobbying exercise promoting the health benefits of low alcohol drinks. AR argued that a fixation on unproven benefits of low alcohol drinks pose a potential barrier to effective action.

App assessed: A study found that large-scale promotion of an app called “Drink Less” could reduce alcohol-related deaths by 4,600 and hospital admissions by 188,400 over the next 20 years,  saving the NHS £590m ($730m).

Features

Opinion: Alcohol-free beer hype is unhelpful
Heavy marketing has created a buzz around alcohol-free beer diverting vital public attention from surging rates of alcohol harm. The stakes are too high to let commercial hype eclipse evidence-based action.

Preview for full subscribers
The case for pure free time hedonism
The New Year is when many of us try to change our habits, resolving to cut back on alcohol, save money and exercise more. But we might also usefully take a step back to ensure our free time satisfies our appetite for feelings and sensation.

Message of the month

Put alcohol pleasure in perspective

Heavy marketing can make it seem that alcohol drinking is essential in pleasure when it really only plays a bit-part, and often a negative one. If we are serious about enjoying our spare time we might benefit from a more open, creative approach, as argued above. ■

Related

Copyright © 2025 · Phil Cain Impressum

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}